Free Trial
→ 'The largest market in human history' (From Behind the Markets) (Ad)tc pixel
NASDAQ:OCUL

Ocular Therapeutix Q3 2026 Earnings Date & Estimates

Ocular Therapeutix logo
$7.51 +0.28 (+3.87%)
Closing price 04:00 PM Eastern
Extended Trading
$7.48 -0.04 (-0.47%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ocular Therapeutix is scheduled to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Ocular Therapeutix in Q3 2026

Ocular Therapeutix is expected to post earnings of -$0.36 per share on revenue of $14.32 million. In the same quarter a year earlier Ocular Therapeutix reported -$0.37 per share on revenue of $14.54 million. Ocular Therapeutix last reported on August 3, 2026, posting -$0.35 per share and beating the -$0.40 consensus estimate. Ocular Therapeutix has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.36
Expected Revenue
$14.32 million
Prior-Year EPS
-$0.37
Prior-Year Revenue
$14.54 million
Expected Revenue Growth
-1.5%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.35 (Beat by +$0.05)
Last Quarter Revenue
$13.48 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Ocular Therapeutix Q3 2026 Earnings FAQ

Ocular Therapeutix (NASDAQ:OCUL) is scheduled to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens.

Ocular Therapeutix's Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Ocular Therapeutix to post earnings of -$0.36 per share for Q3 2026.

The consensus revenue estimate for Ocular Therapeutix is $14.32 million for Q3 2026.

Ocular Therapeutix Earnings Headlines

Ocular Therapeutix (NASDAQ:OCUL) Stock: Insider Jeffrey Heier Sells 10,869 Shares
October 8 at 5:08 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31099079
Ocular Therapeutix, Inc. (OCUL) Presents at Euretina 2026 - Slideshow
October 6 at 7:03 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4952368-ocular-therapeutix-inc-ocul-presents-at-euretina-2026-slideshow
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
October 8 at 1:00 AM  |  Porter & Company (Ad)
Comparing Ocular Therapeutix (NASDAQ:OCUL) and Bausch Health Cos (NYSE:BHC)
October 6 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31090078
Stocktwits Pharma Pulse: Roche faces FDA decision, gene-therapy stocks step into focus — the week’s biotech watchlist
October 4, 2026  |  msn.comhttps://www.msn.com/en-in/science/biology/stocktwits-pharma-pulse-roche-faces-fda-decision-gene-therapy-stocks-step-into-focus-the-week-s-biotech-watchlist/ar-AA2dzEK1
Ocular Therapeutix (NASDAQ:OCUL) Earns "Buy" Rating from Chardan Capital
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083713
See More Ocular Therapeutix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ocular Therapeutix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ocular Therapeutix and other key companies, straight to your email.

About Ocular Therapeutix

Ocular Therapeutix (NASDAQ:OCUL) is a biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company uses its proprietary hydrogel-based formulation and delivery technologies to create sustained-release treatments intended to improve drug delivery, reduce dosing frequency and address unmet needs in ophthalmology.

Its commercial product is DEXTENZA, a corticosteroid ophthalmic insert that is placed in the canaliculus by a healthcare professional. DEXTENZA is approved in the United States for the treatment of ocular itching associated with allergic conjunctivitis and for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix is also advancing a pipeline of investigational treatments for retinal diseases and other ophthalmic conditions, including therapies designed for longer-duration drug delivery.

Founded in 2006 and headquartered in Bedford, Massachusetts, Ocular Therapeutix primarily serves the U.S. ophthalmology market. The company is led by co-founder Antony P. Marucci, who serves as president and chief executive officer. Its products and development programs are supported by research, clinical development and commercial activities focused on the United States.

View Ocular Therapeutix Profile
Earnings Tools